Skip to content

Autologous Stem Cell Therapy for Fracture Non-union Healing

Autologous Stem Cell Therapy for Fracture Non-union Healing

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02177565
Enrollment
35
Registered
2014-06-27
Start date
2000-01-31
Completion date
2011-10-31
Last updated
2020-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-union of Fractures

Keywords

Non-union, fracture, bone marrow stem cells

Brief summary

Do mesenchymal stem cells accelerate new bone formation in persistent non-unions.

Detailed description

Do mesenchymal stem cells accelerate new bone formation in persistent non-unions treated with carrier plus in vitro expanded autologous BMSCs or carrier alone (control). Secondary aims were to analyze predictors of union in these patients and describe adverse events at final follow-up.

Interventions

BIOLOGICALcarrier plus in vitro expanded autologous BMSCs

The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container

Sponsors

Keele University
CollaboratorOTHER
Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 76 Years
Healthy volunteers
No

Inclusion criteria

* An established non-union according to the US Food & Drug Administration criteria14. * Non-union following fracture of tibia or femur suitable for synthetic bone grafting.

Exclusion criteria

1. Skeletal immaturity. 2. Pregnant or breast-feeding. 3. Non-union following pathological fractures. 4. Positive to Hepatitis B, Hepatitis-C or HIV. 5. Infection during BMSC culture.

Design outcomes

Primary

MeasureTime frameDescription
Radiological assessment of new callus and fracture bridging12 monthsThe primary outcome measure was formation of new callus and cortical bridging, assessed from pre-operative and multiple post-operative radiographs and CT-scans up to 12 months. These images were divided into early (0-3 months) and late (9-12 months) groups. Non-unions were assessed from anonymized slides by four independent reviewers (two radiologists and two orthopedic surgeons) blinded to the side of cell insertion. Each slide had a pre-operative radiograph for comparison but no indication of time since surgery, and showed a medial/ lateral or an anterior/ posterior view depending on the surgical approach . At first, each reviewer indicated the side with largest callus and most cortical bridging pre-operatively. Then each reviewer examined subsequent radiographs to indicate the side with the largest increase in new callus and cortical bridging.

Secondary

MeasureTime frameDescription
EQ-5D12 monthsChange in EQ-5D index at 1 year was used as secondary outcome measures.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026